Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Similar documents
Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

Case Scenario 1. 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain.

Case Scenario 1. History

Case Scenario 1. 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain.

UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE

What is endometrial cancer?

Staging and Treatment Update for Gynecologic Malignancies

Endometrial Cancer. Incidence. Types 3/25/2019

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan

11/21/13 CEA: 1.7 WNL

X-Plain Ovarian Cancer Reference Summary

One of the commonest gynecological cancers,especially in white Americans.

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

Quiz. b. 4 High grade c. 9 Unknown

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

General history. Basic Data : Age :62y/o Date of admitted: Married status : Married

Case Scenario 1. Discharge Summary

Case Scenario 1: Thyroid

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

NAACCR Webinar Series /7/17

Kieran Sultan, PGY4 Penrose St. Francis Hospital

Case Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma

Endometrial Stromal Sarcoma


Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Boot Camp Case Scenarios

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Endometrial adenocarcinoma icd 10 code

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Requirements for Abstracted Text

Case Scenario year-old white male presented to personal physician with dyspepsia with reflux.

Pancreas Case Scenario #1

Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:

JMSCR Vol 05 Issue 06 Page June 2017

Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Uterus Malignancies /5/15

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

SEER Summary Stage Still Here!

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

PORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:

Janjira Petsuksiri, M.D

NAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary

Gynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer

Gynaecological Oncology Cases

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

ARROCase: Locally Advanced Endometrial Cancer

ARRO Case: Early-stage Endometrial Cancer

Ovarian Cancer Includes Epithelial, Fallopian Tube, Primary Peritoneal Cancer, and Ovarian Germ Cell Tumors

ENDOMETRIAL CANCER: A GUIDE FOR PATIENTS

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

Index. B Bilateral salpingo-oophorectomy (BSO), 69

Atypical Hyperplasia/EIN

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA

Cervical Cancer: 2018 FIGO Staging

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention

Prostate Case Scenario 1

Guidelines for Assigning Summary Stage 2000

Bilateral Primary Fallopian Tube Carcinoma: Findings on Sequential MRI

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Case Report Advanced Mesodermal (Müllerian) Adenosarcoma of the Ovary: Metastases to the Lungs, Mouth, and Brain

Ovarian Tumors. Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Case Report Serous Ovarian Carcinoma Recurring as Malignant Mixed Mullerian Tumor

Gynecologic Malignancies. Kristen D Starbuck 4/20/18

the session. selected cases

Merkel Cell Carcinoma Case # 2

A patient with recurrent bladder cancer presents with the following history:

Radiation Oncology MOC Study Guide

Article begins on next page

4 Mousa Al-abbadi. Ola Al-juneidi. Abdul-rahman Ibrahim

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Interactive Staging Bee

Endometrial adenocarcinoma icd 10 code

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Algorithms for management of Cervical cancer

Multiple Primary Quiz

Gynecological Cancers in Primary Care

4:00 into mp3 file Huang_342831_5_v1.mp3

M of initial surgical treatment of cancer of

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Transcription:

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES PHYSICAL EXAMINATION CASE 1: FEMALE REPRODUCTIVE 3/5 Patient presents through the emergency room with a chief complaint of severe abdominal pain. She is taken to surgery for exploratory laparotomy. PE: Abdomen is tender on right side. Pelvic: No adnexal masses palpated. Remainder of physical exam is negative. IMAGING 3/5 CT abdomen: 7 cm cystic mass in anterior mid pelvis. LABORATORY None PROCEDURES 3/6 Exploratory laparotomy; bilateral salpingo-oophorectomy; endocervical curettage; endometrial biopsy: Mass in right ovary. Pelvic and abdominal lymph nodes normal. PATHOLOGY 3/6 Biopsy uterosacral ligament: Adenocarcinoma. Bilateral salpingo-oophorectomy: Right ovary; adenocarcinoma, clear cell type, moderately differentiated. Left ovary and tube negative. ECC, EMB: Benign. Ascitic fluid with adenocarcinoma. Probably right ovarian primary with metastasis to right uterosacral ligament. 1

NAACCR Hospital Webinar Case 1 Exercise Abstract Form Primary Site: Laterality: Sequence Number: Histology: Collaborative Staging Data Items CS Tumor Size: CS Extension: CS Tumor Size/Extension Evaluation: CS Lymph Nodes: CS Regional Nodes Evaluation: Regional Nodes Positive: Regional Nodes Examined: CS Metastasis at Diagnosis: CS Mets Eval: SSF 1: SSF 2: SSF 3: SSF 4: SSF 5: SSF 6: 2

CASE 1 (CONTINUED) First Course Treatment Data Items Surgical Procedure of Primary Site: Scope of Regional Lymph Node Surgery: Surgical Procedure/Other Site: Regional Treatment Modality: Boost Treatment Modality: Chemotherapy: Hormone therapy: Immunotherapy: Hematologic Transplant and Endocrine Procedures: Other Treatment: 3

CASE 2: FEMALE REPRODUCTIVE HISTORY AND PHYSICAL EXAMINATION 2/6 This 69-year-old single female presents with feeling so sick, weakness, fatigue, and nausea. Two weeks ago the patient presented with gummy looking discharge from the vagina with swelling. There was no rectal bleeding. IMAGING 2/6 CT abdomen: Large soft tissue mass extends from the uterus and involves the pelvic cavity extending into the left upper quadrant of the abdomen, omentum. There is a large amount of abdominal and pelvic ascites. Multiple densities in the liver are suspicious for metastasis. There is no abdominal or pelvic lymphadenopathy. PROCEDURES 3/2 Scope with rectal biopsy: Extrinsic narrowing with obstruction of lumen. 3/10 Omental biopsy and aspiration of abdominal fluid PATHOLOGY 3/2 Rectal biopsy: Suspicious for malignancy 3/10 Abdominal fluid: Carcinoma, poorly differentiated, favor endometrial primary per pathologist 3/10 Omental biopsy: Poorly differentiated adenocarcinoma 4

NAACCR Hospital Webinar Case 2 Exercise Abstract Form Primary Site: Laterality: Sequence Number: Histology: Collaborative Staging Data Items CS Tumor Size: CS Extension: CS Tumor Size/Extension Evaluation: CS Lymph Nodes: CS Regional Nodes Evaluation: Regional Nodes Positive: Regional Nodes Examined: CS Metastasis at Diagnosis: CS Mets Eval: SSF 1: SSF 2: SSF 3: SSF 4: SSF 5: SSF 6: 5

CASE 2 (CONTINUED) First Course Treatment Data Items Surgical Procedure of Primary Site: Scope of Regional Lymph Node Surgery: Surgical Procedure/Other Site: Regional Treatment Modality: Boost Treatment Modality: Chemotherapy: Hormone therapy: Immunotherapy: Hematologic Transplant and Endocrine Procedures: Other Treatment: 6

PHYSICAL EXAMINATION CASE 3: FEMALE REPRODUCTIVE 4/15/07 Patient presents for pelvic exam. Pelvic: Os wide open with necrotic tissue in cervical os consistent with possible cervical cancer. Uterus is enlarged and slightly tender. IMAGING 4/28/07 Chest x-ray: Negative. 4/28/07 CT of abdomen/pelvis: There is a 7 cm mass arising from the cervix and infiltrating the vaginal wall, probable malignant neoplasm with involved iliac lymph nodes. PROCEDURES 4/27/07 Cervical biopsy and curettage: Examination was performed under anesthesia. There is a 15-16 week pelvic mass in midline. The cervical region contains necrotic tissue emanating from the endocervical area. PATHOLOGY 4/27/07 Cervical biopsy: Moderately differentiated adenocarcinoma. Comment: Histologic features suggest origin from the cervix. 7

NAACCR Hospital Webinar Case 3 Exercise Abstract Form Primary Site: Laterality: Sequence Number: Histology: Collaborative Staging Data Items CS Tumor Size: CS Extension: CS Tumor Size/Extension Evaluation: CS Lymph Nodes: CS Regional Nodes Evaluation: Regional Nodes Positive: Regional Nodes Examined: CS Metastasis at Diagnosis: CS Mets Eval: SSF 1: SSF 2: SSF 3: SSF 4: SSF 5: SSF 6: 8

CASE 3 (CONTINUED) First Course Treatment Data Items Surgical Procedure of Primary Site: Scope of Regional Lymph Node Surgery: Surgical Procedure/Other Site: Regional Treatment Modality: Boost Treatment Modality: Chemotherapy: Hormone therapy: Immunotherapy: Hematologic Transplant and Endocrine Procedures: Other Treatment: 9

PHYSICAL EXAMINATION CASE 4: FEMALE REPRODUCTIVE 1/15/07 Abdomen soft, distended inferiorly by a palpable mass that extended two finger breadths below the umbilicus. There are no other masses. There is no hepatomegaly. The pelvic exam was deferred. IMAGING 1/22/07 Ultrasound of the abdomen & pelvis: Large right adnexal mass with cystic and solid components measuring 14 cm. Smaller 4.5 cm left adnexal mass. The uterus contains fibroids. There is no free fluid, and there is no hydronephrosis. 1/29/07 CT scan, pelvis: Uterus anteriorly displaced by bilateral large cystic and solid masses. The right mass is 10 cm, and the left mass is 4 cm. There are no ascites or implants in the pelvis. There is no evidence of retroperitoneal adenopathy. LABORATORY None remarkable. PROCEDURES 2/15/07 Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, appendectomy, bilateral pelvic and periaortic lymph node sampling: There is no gross ascites. There is a small amount of fluid in the pelvis. The upper abdomen is negative for metastatic disease. There is a large cystic mass in the pelvis stuck behind the uterus. The uterus is small and normal. The mass appears to be coming off of the right ovary. Multiple biopsies were taken along with the surgical resection. PATHOLOGY 2/15/07 The cervix, endometrium, and myometrium are all within normal limits. The bilateral fallopian tubes are negative. The bilateral ovaries both contain serous cystadenocarcinoma. The lymph nodes sampled were negative; 8 left pelvic, 7 right pelvic, and 3 periaortic. There was no malignancy in the omentum or bilateral pelvic gutters. The peritoneal washings showed abnormal clusters of epithelial cells with positive cytology similar to the concurrent surgical specimen. Fine needle aspiration of the diaphragm was benign. 10

NAACCR Hospital Webinar Case 4 Exercise Abstract Form Primary Site: Laterality: Sequence Number: Histology: Collaborative Staging Data Items CS Tumor Size: CS Extension: CS Tumor Size/Extension Evaluation: CS Lymph Nodes: CS Regional Nodes Evaluation: Regional Nodes Positive: Regional Nodes Examined: CS Metastasis at Diagnosis: CS Mets Eval: SSF 1: SSF 2: SSF 3: SSF 4: SSF 5: SSF 6: 11

CASE 4 (CONTINUED) First Course Treatment Data Items Surgical Procedure of Primary Site: Scope of Regional Lymph Node Surgery: Surgical Procedure/Other Site: Regional Treatment Modality: Boost Treatment Modality: Chemotherapy: Hormone therapy: Immunotherapy: Hematologic Transplant and Endocrine Procedures: Other Treatment: 12

EVALUATION & CONSULTATION CASE 5: FEMALE REPRODUCTIVE 2/2/07 The patient is a 52-year-old female. Today, I had a very lengthy discussion with this patient and her family with regards to her recent diagnosis of endometrial carcinoma, most likely carcinosarcoma. I explained to her that the treatment options are as follows: 1. Do nothing, which I do not recommend. 2. Undergo surgical therapy consisting of hysterectomy, bilateral salpingo-oophorectomy and possible lymph node dissection. If indicated she will then need postoperative radiation therapy or chemotherapy. 3. Primary radiation therapy would be appropriate if she refuses surgery. 4. Primary chemotherapy would not be considered appropriate at this time. After a very lengthy discussion of the risks, benefits, and treatment options, the patient and her family mentioned that she would like to proceed with surgical therapy. 2/28/07 Today, I had a lengthy discussion with the patient with regard to her diagnosis of malignant mixed mullerian tumor of the uterus. I explained to her that the depth of invasion was more than 50% (51%). Given this, one would consider that she has high risk features. I explained to her that the treatment options at this time are as follows: 1. Do nothing but just proceed with conservative therapy consisting of Pap smears every three months. 2. Undergo postoperative radiation therapy. 3. Undergo postoperative chemotherapy. I have explained that the literature does not support any increase in survival whether chemotherapy or radiation therapy is used. The major difference regarding chemo or radiation therapy is site of recurrence. At this time, however, given the fact that the patient did have a preoperative CT scan that did not demonstrate any evidence of metastatic disease to the chest or the upper abdomen, it may not be unreasonable to treat her with radiation therapy. I have asked her to take this into consideration, and I will further discuss her case with our radiation oncology service to develop a plan for her. The patient is agreeable to this. 3/19/07 Radiation Oncology I had a lengthy discussion with the patient today about the rationale for giving local radiation therapy. While we cannot infer any benefit in terms of long-term survival, we can decrease the chance of regrowth of tumor within the pelvis. For this reason, I am recommending treatment. The patient is scheduled to meet with a radiologist near her home this coming week. He will organize treatments if he agrees with this plan. LABORATORY 2/28/07 Estrogen and progesterone receptor immunoperoxidase stains Interpretation: Uterus, cervix, bilateral ovaries and fallopian tubes, hysterectomy, bilateral salpingo-oophorectomy: Malignant mixed mullerian tumor, heterologous type. 1. Negative for estrogen receptors. 2. Positive for progesterone receptors (in 5% of tumor cells). Carcinosarcoma (malignant mixed Mullerian tumor). 13

(CASE 5 CONTINUED) PROCEDURES 1/24/07 Curettage, endocervix and endometrium 2/21/07 Operative laparoscopy, extensive lysis of adhesions of omentum from the anterior abdominal wall, extensive lysis of adhesions of the bowel to the right and left adnexae, laparoscopic total hysterectomy, bilateral salpingo-oophorectomy, cystoscopy, and bilateral pelvic lymph node sampling. PATHOLOGY 1/24/07 Endometrium: Carcinosarcoma (malignant mixed Mullerian tumor). 2/21/07 A. Uterus, cervix, bilateral ovaries and fallopian tubes, hysterectomy, bilateral salpingooophorectomy a. Endomyometrium i. Malignant mixed mullerian tumor, heterologous type ii. Tumor grade: FIGO grade III iii. Tumor size and depth of invasion (AJCC:pT1c) 1. Tumor measures 5.5 cm in greatest dimension 2. Tumor invades 51% of the total myometrial thickness a. Tumor location: 100% of the endometrium including lower uterine segment i. Anterior and posterior wall b. Lymphovascular invasion: Not identified. See comment. c. Margins: Resection margins negative for tumor. d. Leiomyomata, intramural (largest measuring 0.8 cm in greatest dimension). b. Cervix: negative for tumor. c. Serosa: No pathologic features. d. Ovaries, bilateral: No pathologic features e. Fallopian tubes, bilateral: No pathologic features. B. Lymph nodes, left pelvic, excision: a. Five lymph nodes negative for metastatic tumor (0/5). C. Lymph nodes, right pelvic, excision: a. One lymph node negative for metastatic tumor (0/1). Comment: The majority of this malignant mixed mullerian tumor is composed of an epithelial (carcinomatous) component. However, foci of cartilaginous and osseous sarcomatous transformation are present. This tumor is exophytic and occupies the entire endometrial cavity, including the lower uterine segment. The cervix, however, is free of tumor. The lymph nodes are also negative for metastatic carcinoma. This case was reviewed at the interdepartmental consultation conference. ER/ PR stains have been ordered and are pending. 14

HISTORY CASE 6: FEMALE REPRODUCTIVE 6/15/07 The patient is 33-year-old woman who presented with a 2-month history of post-coital bleeding and vaginal discharge. She has three healthy children via normal spontaneous vaginal deliveries. She has taken oral contraceptives for the past 7 years, but she now has an IUD in place for contraception. PAP smear and subsequent biopsy showed carcinoma. IMAGING 6/1/07 Chest x-ray: Normal. PROCEDURES 6/15/07 Hysterectomy with bilateral salpinooophorectomy: Uterus with pelvic and periaortic lymph nodes; 5 x 3.7 x 2cm bulky exophytic mass involving the posterior and lateral cervix. Tumor involved 75% of cervical wall, but it did not extend into the endomyometrium. The vaginal cuff, parametria and bilateral adnexa were grossly free of tumor. PATHOLOGY 6/15/07 FINAL DIAGNOSIS: 1. Poorly differentiated glassy cell carcinoma (adenosquamous) of the cervix, 5.0 cm, involving 75% of the cervical wall. All resection margins are free of carcinoma. 2. All lymph nodes are negative for carcinoma. 15

NAACCR Hospital Webinar Case 6 Exercise Abstract Form Primary Site: Laterality: Sequence Number: Histology: Collaborative Staging Data Items CS Tumor Size: CS Extension: CS Tumor Size/Extension Evaluation: CS Lymph Nodes: CS Regional Nodes Evaluation: Regional Nodes Positive: Regional Nodes Examined: CS Metastasis at Diagnosis: CS Mets Eval: SSF 1: SSF 2: SSF 3: SSF 4: SSF 5: SSF 6: 16

CASE 6 (CONTINUED) First Course Treatment Data Items Surgical Procedure of Primary Site: Scope of Regional Lymph Node Surgery: Surgical Procedure/Other Site: Regional Treatment Modality: Boost Treatment Modality: Chemotherapy: Hormone therapy: Immunotherapy: Hematologic Transplant and Endocrine Procedures: Other Treatment: 17